Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Northwell's"


3 mentions found


Northwell Health, New York's largest health system, is making a big investment in generative AI. It's working through an AI partnership with Aegis Ventures to make new products for providers. New York's largest health system is deepening its push into generative AI, the hot new technology taking the business world by storm. Northwell Health is gearing up for this effort by working with Aegis Ventures, a startup studio that's committed $100 million to joint ventures with Northwell. The team at Northwell that deals with billing health plans is also interested in taking advantage of AI, Mulry said.
Persons: that's, Mark Michalski, it's, Michalski, It's, Gregg Fergus, Richard Mulry, Mulry, Billing, Northwell, Marc Paradis Organizations: Health, Aegis Ventures, Northwell, Amazon, Northwell Holdings, Aegis, Northwell's, Microsoft Locations: Michalski
NYU Langone is suing Northwell Health, alleging it created "confusingly similar advertisements." "This case is about deceptive business practices," lawyers for NYU Langone wrote in the lawsuit. NYU Langone filed a lawsuit Thursday alleging that neighboring New York hospital system and known competitor, Northwell Health, copied its signature purple-colored advertisements to create "confusingly similar advertisements" in the New York area. "This case is about deceptive business practices," lawyers for NYU Langone wrote in the lawsuit. In a response to the suit, Northwell Health called NYU's claims "preposterous."
Persons: NYU Langone, Northwell, Steve Ritea, Ritea, Ramon Soto Organizations: NYU, Northwell, Morning, New York's Southern, Court, NYU Langone, US News Locations: New York, New York's, United States
If successful, Merck could begin marketing the new formulation within a few years, a top Merck executive told Reuters. "The clock for that patent would start ticking from the time we would get that patent approved." Drug patents have a guaranteed term of exclusivity for 20 years after receiving a patent under U.S. law, but sometimes the companies are able to add additional patents that extend their exclusivity. Merck's patents on the subcutaneous version of Keytruda could protect that formulation until at least 2040, according to Tahir Amin, co-founder of drug patents watchdog group Initiative for Medicines, Access & Knowledge (I-MAK). Northwell's Mulloy said moving patients to subcutaneous versions of drugs also opens up spots in infusion centers for additional patients.
Total: 3